Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma

OBJECTIVE: Iodine-131-labelled meta-iodobenzylguanidine ((131)I-mIBG) therapy is an established treatment modality for relapsed/refractory neuroblastoma, most frequently administered according to fixed or weight-based criteria. We evaluate response and toxicity following a dosimetry-based, individua...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Sally L., Falzone, Nadia, Chittenden, Sarah, Kirk, Stephanie J., Lancaster, Donna, Vaidya, Sucheta J., Mandeville, Henry, Saran, Frank, Pearson, Andrew D.J., Du, Yong, Meller, Simon T., Denis-Bacelar, Ana M., Flux, Glenn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819901/
https://www.ncbi.nlm.nih.gov/pubmed/26813989
http://dx.doi.org/10.1097/MNM.0000000000000470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819901/
https://www.ncbi.nlm.nih.gov/pubmed/26813989
http://dx.doi.org/10.1097/MNM.0000000000000470

Ejemplares similares